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Abstract: Temporomandibular disorders (TMD) are progressive degenerative disorders that affect the
components of the temporomandibular joint (TMJ), characterized by pain and limitations in function.
Matrix metalloproteinases (MMP) are enzymes involved in physiological breakdown of tissue that can
have a pathological effect from an increase in activity during inflammation. A PubMed search of the
current literature (within the past 10 years) was conducted to identify human studies involving matrix
metalloproteinases activity in TMJ components of patients with TMD. Two separate searches results
in 34 studies, six of which met inclusion criteria. Immunohistochemistry and gene analysis were used
to evaluate MMP expression in the study groups. This review showed the strongest evidence for
involvement of MMP-1, MMP-2, and MMP-9 in TMD; however, limitations included low sample sizes
and a lack of recent clinical studies. Future research with more definitive conclusions could allow for
additional pharmaceutical targets in MMP when treating patients with temporomandibular disorders.
Keywords: matrix metalloproteinases; temporomandibular joint disorder; temporomandibular joint
1. Introduction
The temporomandibular joint (TMJ) is classified as a ginglymoarthrodial joint, allowing for
rotational and translational movements in normal function. Its primary components include the glenoid
fossa of the temporal bone, the articular disc, the head of the mandibular condyle, and masticatory
muscles. This joint is capable of remodeling even after growth has stopped, allowing it to make
structural changes and adapt to different physiological demands [1].
Temporomandibular disorders (TMD) are a group of degenerative disorders involving the
components of the TMJ, which can lead to displacement of the disc, joint remodeling, and eventually
osteoarthritis [2]. Disc displacement can occur anteriorly, posteriorly, medially, or laterally; however,
it is most commonly displaced anteriorly [3]. TMD affects around 25% of the population, and it is
characterized by orofacial pain, restricted range of motion, joint dysfunction, and ultimately, a decreased
quality of life [2,4]. The etiology of TMD is still a topic of discussion; however, some known risk
factors include trauma and microtrauma, malocclusion, and psychological factors, such as stress and
anxiety [5].
The progression of TMD is classified primarily based on the location of the disc and its mobility
during mandibular movement. In a normal functioning joint, the disc remains between the head of
the mandibular condyle and the glenoid fossa through the full range of movement. In early stage
TMD, the disc is displaced anteriorly when the mandible is closed and reduces to a normal location
upon opening, classified as anterior disc displacement with reduction (ADDwR). In late stages of
TMD, the disc is anteriorly displaced in both closed and open positions, classified as anterior disc
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displacement without reduction (ADDwoR). These later stages tend to be associated with more pain
and limitation in mandibular mobility [2].
A more advanced staging guide to the internal derangements of TMD was created by Wilkes in
1989, placing patients into five categories based on clinical, radiographic (tomographic, arthrographic,
and magnetic resonance imaging) and findings during surgery, including gross surface and anatomic
changes to the disc and other components of the TMJ [6]. In the first stage, the early stage, patients present
with clicking of the joint, but no pain, limited range of motion, or other symptoms. Radiographically
and surgically, the disc is displaced slightly anteriorly, but all other aspects of the joint are normal.
In Wilke’s early/intermediate stage, the patient presents with additional symptoms, including episodes
of pain, tenderness, and mechanical problems associated with the joint. Radiographically and surgically,
the disc is displaced anteriorly, with slight deformation of its posterior aspect. In the intermediate stage
there are more occurrences of pain, mechanical problems, including locking and decreased range of
motion. In Wilke’s intermediate/late stage of TMD, the patient has a chronic pain and decreased range
of motion. Radiographically and surgically, an increased severity in comparison to the intermediate
stage is noted, along with remodeling of the hard tissue surfaces of the joint. The disc, however,
has yet to be perforated up to this stage. In the final stage, the late stage, patients present with
crepitus and grinding in the joint with mandibular movement, chronic pain, restricted range of motion,
and an overall decrease in function. Radiographically and surgically, the disc and hard tissues of
the joint have undergone significant deformation, remodeling, and arthritic changes have occurred,
including perforations of the attachments and erosion of articulating surfaces [6].
Matrix metalloproteinases (MMPs) are the major enzymes involved in extracellular matrix
(ECM) and basement membrane remodeling and degradation, along with other enzymes, such as
a disintegrin and metalloproteinases (with or without thrombospondin), and plasminogen activators,
among others [7–9]. These enzymes are seen in both physiological and pathological processes,
including embryogenesis, apoptosis, bone remodeling, inflammation, arthritis, and cancer [7,8].
However, the role of MMPs is not limited to the ECM, as they have also been shown to play a role
in regulating inflammatory response, namely by processing chemokines, growth factors, receptors,
proteases, and other molecules and proteins [9]. They are a family of 26 endopeptidases that degrade
collagen, gelatin, proteoglycans, and other ECM components, and they are regulated at the level of
their gene expression (cytokines, growth factors, hormones, and others), posttranslational activation,
and endogenous inhibition (tissue inhibitors of metalloproteinases [TIMP]) [8,10]. As inflammation
occurs, however, processes involving these enzymes shift from physiological to pathological, and MMP
activity results in excess tissue breakdown and damage [11].
Some MMPs have been suggested as being involved in angiogenesis, apoptosis, and osteoarthritis,
processes which are seen in temporomandibular joint disorders [7]. Angiogenesis, found mostly in the
synovial membrane in TMD, allows for new vessel formation to combat the hypoxia associated with
an increase in the intra-articular pressure seen in TMD [12]. Chondrocytes undergo apoptosis in the
early stages of TMD as the disc begins to remodel, and eventual cartilage degradation occurs, leading
to osteoarthritic changes [4]. With evidence of the involvement of MMPs in these processes, and with
the processes playing a crucial role in the progression of TMD, it would seem that MMP activity would
be increased in joints of patients with the disorder. This paper aims to review the current scientific
literature in order to investigate potential links between various MMPs and TMD.
2. Methodology
2.1. Search Protocol
Two independent electronic searches were conducted by two reviewers using PubMed to find
relevant literature using Medical Subjective Headings (MeSH) Terms. The MeSH terms included in
each search were:
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1. “Temporomandibular Joint Disorders/enzymology” (Mesh) OR “Temporomandibular
Joint Disorders/metabolism” (Mesh) OR “Temporomandibular Joint Disorders/pathology”
(Mesh)) AND “Humans” (Mesh)) AND “Immunohistochemistry” (Mesh)) AND “Matrix
Metalloproteinases” (Mesh)
2. “Temporomandibular Joint Disorders” (MeSH Major Topic) AND “Matrix Metalloproteinases”
[MeSH Major Topic]) AND “Humans” (MeSH Terms)
2.2. Selection Protocol
Inclusion and exclusion criteria were determined before the search results were evaluated.
Inclusion criteria used in selection included the following:
1. English language;
2. Living human subjects;
3. Publication within the past 10 years (since 2009);
4. Studies that evaluated samples of TMD and the level of MMP in the disease.
Exclusion criteria used in selection included the following:
1. Case studies;
2. Pilot studies;
3. Literature reviews.
2.3. Data Analysis
The data collected from each selected study, summarized in Table 1, included MMP type assessed
in the study, sample size and groups, mean age involved in study, TMJ assessment, and the results
of the study. Since the studies differed significantly in their methodology, a direct data analysis was
unable to be conducted, and further evaluation of the quality of the included studies, such as statistical
power, was not done beyond looking at the sample size.
Table 1. Studies that fit the inclusion criteria and published within the past 10 years [11,13–17]. Anterior
disc displacement with reduction (ADDwR); anterior disc displacement without reduction (ADDwoR);
matrix metalloproteinases (MMP); temporomandibular joint (TMJ).
Included Researcher’s Characteristics and Main Results
Authors ExperimentalSample
Age of
Experimental
Sample (Mean)
MMP
Assessed and Method TMJ Assessment Result
Perotto et al.,
2018
Group 1: Healthy 8
Samples
Group 2: ADDwR
21 Samples
Group 3: ADDwoR
10 Samples
33.59
MMP-13
Immuno-
Histochemical
Staining (IHC)
Clinical Examination,
Symptoms, Panorex
No significant different
in MMP-13 expression
Almeida et al.,
2014
45 Samples from 33
Subjects 32.26
MMP-2, MMP-9
IHC
Clinical Examination,
Symptoms, Panorex
Upregulation of
MMP-2. No significant
difference in MMP-9
expression.
Loreto et al.,
2013
25 Samples from 25
Subjects 34.2
MMP-7, MMP-9
IHC
Clinical Examination,
Symptoms, MRI
Upregulation of both
MMP-7 and MMP-9.
Planello et al.,
2011
115 Samples from
115 Subjects 42.82
MMP-1, MMP-3, MMP-9
DNA Purification, PCR,
Genotype Analysis
CT Imaging, MRI,
History of Symptoms
Upregulation of
MMP-1. No
association with
MMP-3 and MMP-9.
Milosevic et al.,
2015
100 Samples from
100 Subjects 37.12
MMP-9
DNA Extraction,
Genotype Analysis, PCR
Clinical Evaluation,
History of Symptoms
Upregulation of
MMP-9.
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Table 1. Cont.
Included Researcher’s Characteristics and Main Results
Authors ExperimentalSample
Age of
Experimental
Sample (Mean)
MMP
Assessed and Method TMJ Assessment Result
Luo et al.,
2015
Group A: 185
Healthy
Group B: 141
ADDwR
Group C1: 115
ADDwoR w/o OA
Group C2: 206
ADDwoR w/ OA
Group A: 33.49
Group B: 36.64
Group C: 37.22
MMP-1
DNA Sampling,
Genotype Analysis
Clinical and
Radiographic
Examinations,
Symptoms
Upregulation of
MMP-1 in ADDwoR
with or without TMJ
osteoarthritis.
3. Results
3.1. General Outcomes
Initial searches using the MeSH terms indicated above resulted in 34 studies, nine of which were
duplicates and three of which were unable to be accessed. After removing duplicates and inaccessible
studies, 22 studies remained. One study was not included due to samples being cadaveric, one focused
on interleukins (IL) and used unspecified MMPs as markers for IL, two were animal studies, and two
others were literature reviews. All other studies satisfied both the English language and the living
human subject inclusion criteria, leaving 16 total studies. After including only studies published within
the past 10 years, 6 studies remained, all of which were accepted based on all other indicated inclusion
and exclusion criteria. Studies with researcher’s characteristics and main results excluded from this
review due to date of publication are included in Table 2 for additional comparison.
Table 2. Studies that fit all inclusion criteria, but were published more than 10 years ago [18–27].
Excluded Researcher’s Characteristics and Main Results
Authors ExperimentalSamples
Age of
Experimental
Samples (Mean)
MMP
Assessed and Method TMJ Assessment Result
Tiilikainen et
al., 2005
54 Samples
from 54
Subjects
36.3 MMP-3, MMP-8IHC
Clinical Examination,
CT, MRI, Symptoms
No significant difference
between severity of
TMD in expression of
MMP-3 or MMP-8.
Ishimaru et
al., 2000 94 Samples 31.33
MMP-1, MMP-3
IHC
Clinical Examination,
Panorex, Arthrograms,
Visual Analog Score
Calculations
Upregulation of both
MMP-1 and MMP-3.
Kanyama et
al., 2000
10 Samples
from 10
Subjects
29.7
MMP-1, MMP-2, MMP-3,
MMP-9
IHC
Clinical Examination,
MRI, Symptoms
Upregulation of MMP-1,
MMP-2, MMP-3 and
MMP-9.
Marchetti et
al., 1999 11 Subjects
No Mean
Range: 26–43
MMP-2
IHC
MRI and Macroscopic
Examination Upregulation of MMP-2.
Yoshida et al.,
1999 16 Subjects 41.12
MMP-3
IHC - Upregulation of MMP-3.
Fujita et al.,
2008
54 Samples
from 50
Patients
36.2
MMP-3
Enzymography, Western
Blot Analysis, Immuno-
precipitation
Clinical and
Radiographic
Examinations,
Upregulation of MMP-3.
Srinivas et al.,
2000 44 Subjects 36
MMP-2, MMP-8, MMP-9
Enzyme Activity, Western
Immunoblotting
Symptoms, Clinical and
Radiographic
Examination, Surgical
Observation
Upregulation of MMP-2,
MMP-8, and MMP-9
Yoshida et al.,
2006
44 Samples
from 35
Subjects
36.6
MMP-2, MMP-9
Sample Collection, MRI,
Western Immunoblotting
Clinical Examination,
MRI, Symptoms
Upregulation of MMP-2
and MMP-9.
Appl. Sci. 2019, 9, 4508 5 of 9
Table 2. Cont.
Excluded Researcher’s Characteristics and Main Results
Authors ExperimentalSamples
Age of
Experimental
Samples (Mean)
MMP
Assessed and Method TMJ Assessment Result
Mizui et al.,
2001 86 Subjects Range: 19–84
MMP-2
Proteolytic Activity,
Enzymogram
Radiographic Analysis Upregulation of MMP-2.
Tanaka et al.,
2001
41 Samples
from 38
Subjects
34.8
MMP-2, MMP-9
Enzyme Activity, Immuno-
blotting, Gelatinolytic
Activity
Symptoms, Clinical and
Radiographic Exam
MMP-2 and MMP-9
were upregulated more
in ADDwoR than in
ADDwR.
3.2. Description of Included Studies
In 2018, Perotto et al. used 39 disc samples from 27 patients to look at MMP-13 expression in
TMD. Exclusion criteria for subjects Perotto’s study included use of orthodontic appliances, chronic
anti-inflammatory use, history of diseases causing impaired immune function, such as HIV, diabetes,
or any use of immunosuppressive therapy. The patients, with a mean age of 33.59, then filled out
a pain questionnaire, had a clinical examination, and radiographs or CT imaging was performed
for diagnostic purposes, placing patients into groupings of either ADDwR or ADDwoR. Surgery
was performed on patients and samples were obtained and underwent immunohistological staining
to analyze for MMP-13 activity. The researchers did not find a significant difference in expression
of MMP-13 in samples from patients with TMD, in either the ADDwR or the ADDwoR groupings,
when compared to the control group.
Almeida et al. (2014) analyzed activity of two matrix metalloproteinases and their protein levels in
TMD, both MMP-2 and MMP-9. In this study, 45 disc samples from 33 patients (mean age of 32.36 years)
were analyzed using immunohistological staining. Diagnosis was made using a pain questionnaire and
clinical examination, grouping patients into ADDwR and ADDwoR, and selected patients were treated
surgically following unsuccessful non-surgical treatment. Following immunohistochemical staining of
samples obtained during surgery, MMP-2 was found to be significantly increased in samples from
subjects with TMD when compared to the control. It was also found that there was an increase in
MMP-2 in samples from patients with ADDwoR when compared to ADDwR, suggesting a correlation
between progression of TMD and MMP-2 levels. Levels of MMP-9 showed no significant difference
between the TMD disc samples when compared with control disc samples.
Loreto et al. (2013) used immunohistochemical staining to look at MMP-7 and MMP-9 in disc
samples from subjects with TMD. They used 25 disc samples from 25 patients (mean age of 34),
which were obtained surgically following unsuccessful non-surgical intervention after diagnosis using
a history of present illness, clinical examination, and MRI. They assessed the severity of the disease
by looking at unassisted maximum mouth opening and using a visual analog scale to assess pain.
Following staining, both MMP-7 and MMP-9 were found to be expressed at levels significantly higher
in samples from patients with TMD when compared to control samples.
Planello et al. (2011) analyzed the frequency of polymorphisms in genes coding for MMP-1,
MMP-3, and MMP-9 proteinases in patients with TMJ degeneration. The study was conducted on
232 individuals, 115 of which had TMJ degeneration and a mean age of 42.82. To diagnose the study
group, the researchers used MRI and/or CT scans to image one or both mandibular condyles. Genomic
DNA was gathered from epithelial buccal cells and a PCR reaction was performed for MMP-1, MMP-3,
and MMP-9 coding genes. A genotype analysis using restriction fragment length polymorphisms
was performed, and the frequency of each allele was determined in both groups. Compared to the
control group, there was a statistically significant association between the MMP-1 genotype and the
TMJ degeneration group. No association was found between the MMP-3 and MMP-9 genotypes and
TMJ degeneration.
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Milosevic et al. (2015) studied polymorphisms of multiple genes in order to investigate their role in
TMD. The study included 182 healthy individuals and 100 patients with TMD, with a mean age of 37.12.
The TMD in the study group was assessed using clinical signs and symptoms. Genomic DNA was
gathered from buccal swabs and genotyping was conducted in order to evaluate MMP-9 polymorphisms,
as well as other enzyme polymorphisms outside the scope of this review. The researchers found
a significant difference in genotype and allele frequency in the MMP-9 gene of TMD patients when
compared to the control group.
Luo et al. (2015) studied polymorphisms of MMP-1 genes in healthy individuals and patients with
articular disc derangement and TMJ osteoarthritis. The researchers split patients into three groups,
as follows: Group A included 185 healthy individuals; Group B included 141 patients with unilateral
ADDwR; and Group C included 321 patients with ADDwoR, 115 of which did not present TMJ
osteoarthritis (C1) and 206 of which presented TMJ osteoarthritis (C2). These patients were diagnosed
through clinical and radiographic examinations. Genomic DNA was extracted from buccal swabs
and a PCR analysis was conducted in order to assess variations in the MMP-1 gene. Comparisons
between the groups showed a variety of allele distributions. Groups A and B did not show a significant
statistical difference. Groups A and C showed a noticeable statistical difference with an odds ratio of
2.455 after adjusting for age. When observing the subgroups in Group C, Group C1 had no difference
with group B, while Group C2 had a significant statistical difference and an odds ratio of 1.912. Groups
C1 and C2 showed no significant statistical difference. Overall, their findings suggest the MMP-1 gene
is upregulated in patients with ADDwoR, and the presence of TMJ osteoarthritis had no influence.
4. Discussion
Differences in study design, groupings of samples, and MMPs analyzed prevented direct analysis
of data in the present studies. Three studies, those of Perotto, Almeida, and Luo, not only grouped
samples on the presence and absence of TMD, but also in the degree to which the disease had progressed,
either ADDwR or ADDwoR. Many of the studies analyzed different MMPs, and there were different
techniques used to test for expression of the MMP, including immunohistochemical staining and PCR.
Four of the included studies, those of Almeida, Loreto, Planello, and Milosevic, analyzed the same
MMP, MMP-9, and while Almeida and Planello found that there was no significant different in samples
from subjects with TMD, Loreto and Milosevic found an increase in expression. The Kanyama study in
2000, the Srinivas study in 2000, the Yoshida study in 2006, and the Tanaka study in 2001, which were
excluded due to date of publication, found that MMP-9 was upregulated in disc samples from subjects
with TMD. The inconclusiveness as to whether or not there is a correlation between the levels of MMP-9
expression and TMD of some of the studies can likely be contributed to the small sample size in each.
Aside from MMP-9, the only other overlap of MMP in the included studies was MMP-1, which was
found to be upregulated in TMD samples in both the study conducted by Planello, as well as the
study conducted by Luo. Aside from these two MMPs, there is no additional overlap between MMPs
analyzed in the included studies; however, there is some ability to compare with the studies excluded
due to date of publication. MMP-2, which was found by Almeida to be upregulated in disc samples
from subjects with TMD, was also found to have higher expression in TMD samples by Kanyama,
Marchetti, Srinivas, Mizui, and Tanaka.
Based on the information present in the included studies, it is difficult to draw a definitive
conclusion with respect to the involvement of most MMPs in TMD, even when the studies that were
excluded due to date of publication are considered. The strongest evidence for MMP involvement
in TMD lies with MMP-1, MMP-2, and MMP-9; however, there were limitations in all of the studies,
the biggest being sample size, which ranged from only 25 to 141 samples in the included studies.
5. Conclusions
Despite the high prevalence of TMD in the population, current treatment modalities tend to
have a poor long-term success and few patients seek treatment [2]. The available modalities are
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diverse, ranging from non-invasive techniques, such as physical therapy, ultrasound, low-level laser
therapy, and splints, to minimally invasive techniques, such as corticosteroid injections, arthrocentesis
of the joint, with or without platelet-rich plasma or hyaluronic acid injections, and arthroscopic
surgery, to invasive procedures for the more advanced stage of TMD, which include discectomy,
disc replacement, and the most invasive, total joint replacement [2,28,29]. It is recommended that
attempts at treatment begin with non-invasive techniques and progress to invasive techniques, as risks
with the invasive techniques involving open joint surgery can include facial nerve and optic lesions,
transarticular and intracranial perforations, and pre-auricular hematoma, among others [3]. Further
limitations and complications of arthroscopy, arthrocentesis, and orthognathic surgery used for
treatment of TMD include arteriovenous fistula, pseudoaneurysm, infection, broken instruments in
the joint, and condylar resorption [30,31]. Additionally, bruxism and dysfunctional oral habits have
been shown to be risk factors for recurrent TMD symptoms after orthognathic surgery [32]. Due to
limitations and complications of surgery, it is necessary to develop more efficacious techniques in
non-invasive and pharmaceutical therapies for treating TMD.
Some of the pharmaceutical therapies for TMD include botox and cyclobenzaprine, which induce
muscle relaxation, NSAIDs, and corticosteroids, which reduce pain and inflammation, and tricyclic
antidepressants, which work to reduce pain [33]. However, these agents work to target the effects that
TMD has on the patient rather than an underlying cause. To the researchers’ knowledge, there are
currently no pharmaceutical agents that are used to target an element of the underlying pathogenesis
of TMD, such as MMPs, to stop the progression of this debilitating disorder.
There is ongoing pharmaceutical research to uncover potential MMP inhibitors for therapeutic
use in different disease processes, such as cancer [34]. Thus far, however, limitations have prevented
identification of a suitable therapeutic agent. The poorly understood specificity of their biological
substrates makes it difficult to target specific MMPs, which causes detrimental problems, as MMPs
are vital to survival [34]. There have been additional problems in its use, some of which include
problems with oral bioavailability, toxicity, and metabolic stability [34,35]. Despite the unsuccessful
attempts, knowledge of MMPs continues to evolve and the use of new and future technological
advances, including use of CRISPR-Cas9 and MMP-activatable optical probes, make the use of MMP
as a pharmaceutical target more hopeful [34,35]. If and when a successful pharmaceutical agent is
discovered targeting MMPs, having a good understanding of the specific MMPs involved in TMD
progression could provide an expedited route to applying the therapy to TMD treatment.
More studies with larger sample sizes are needed to analyze the involvement of specific MMPs in
TMD. With more concrete evidence of its role, and because of the nature of the enzymes, MMPs could
prove to provide a better understanding of the progression of TMD and be a valuable pharmaceutical
target for therapy.
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